Gurdon Institute

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

 Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Retrieved on: 
Wednesday, May 18, 2022

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.

Key Points: 
  • Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.
  • Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease.
  • Combining population genetics with Adrestias synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the worlds most intractable diseases.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases.

Owl Labs Becomes a Partner of NAHT

Retrieved on: 
Tuesday, January 11, 2022

--ENDS–

Key Points: 
  • Owl Labs will offer its flagship product, the Meeting Owl Pro to NAHT members at a discounted rate.
  • Frank Weishaupt, CEO of Owl Labs says: Were delighted to be a partner of NAHT to help support the UKs leading school leaders union with best in class technology.
  • Mark Cornell, NAHT Chief of Staff says: Partnering with a company like Owl Labs allows us to offer more cutting-edge technology tools to our members.
  • Owl Labs has raised 15.8 million in funding and is based in Boston, with remote and hybrid employees all over the world.